首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

ANTIVIRAL THERAPY
ISSN：1359-6535

ANTIVIRAL THERAPY

ANTIVIR THER
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：偏慢,4-8周
新锐分区：医学3区
年发文量：11
影响因子：2.3
JCR分区：Q3

基本信息

《抗病毒治疗》（英语：Antiviral Therapy）是国际抗病毒研究学会的官方出版物，是一份国际性的同行评审期刊，专门发表关于抗病毒药物和疫苗的临床开发和使用以及所有病毒性疾病治疗的文章。《抗病毒治疗》是病毒学和感染性疾病的主要期刊之一。该杂志内容全面，发表有关抗病毒治疗所有临床方面的文章。它以社论、原创研究论文、特别委托的评论文章、信件和书评为特色。该杂志面向对临床和基础研究感兴趣的医生和专家。
1359-6535SCIE/Scopus收录
2.3
点击查看最新影响趋势>
3.1
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
INFECTIOUS DISEASES 传染病学
3区
PHARMACOLOGY & PHARMACY 药学
3区
VIROLOGY 病毒学
3区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：INFECTIOUS DISEASES
SCIE
Q3
76/137
学科：PHARMACOLOGY & PHARMACY
SCIE
Q3
202/352
学科：VIROLOGY
SCIE
Q3
24/42
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：INFECTIOUS DISEASES
SCIE
Q4
103/137
学科：PHARMACOLOGY & PHARMACY
SCIE
Q4
266/353
学科：VIROLOGY
SCIE
Q3
31/42
78
11
点击查看年发文量趋势图>
5%较难偏慢,4-8周-医学-病毒学
0%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
100.00%98.57%-
CiteScore：3.80
SJR：0.627
SNIP：0.509
学科类别分区排名百分位
大类：Medicine
小类：Infectious Diseases
Q2
176 / 357
大类：Medicine
小类：Pharmacology (medical)
Q2
136 / 275
大类：Medicine
小类：Pharmacology
Q3
184 / 321

期刊高被引文献

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
来源期刊：Antiviral therapyDOI：10.3851/IMP3293
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
来源期刊：Antiviral therapyDOI：10.3851/IMP3323
Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
来源期刊：Antiviral therapyDOI：10.3851/IMP3314
Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
来源期刊：Antiviral therapyDOI：10.3851/IMP3280
Frailty as a predictor of falls in HIV-infected and uninfected women.
来源期刊：Antiviral therapyDOI：10.3851/IMP3286
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
来源期刊：Antiviral therapyDOI：10.3851/IMP3278
Efavirenz pharmacokinetics during pregnancy and infant washout.
来源期刊：Antiviral therapyDOI：10.3851/IMP3283
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
来源期刊：Antiviral therapyDOI：10.3851/IMP3263
Performance assessment of a fully automated deep sequencing platform for HCV resistance testing.
来源期刊：Antiviral therapyDOI：10.3851/IMP3318
Autophagy involved in antiviral activity of sodium tanshinone IIA sulfonate against porcine reproductive and respiratory syndrome virus infection in vitro.
来源期刊：Antiviral therapyDOI：10.3851/IMP3268
Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.
来源期刊：Antiviral therapyDOI：10.3851/IMP3281
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
来源期刊：Antiviral therapyDOI：10.3851/IMP3277
Impact of three decades of antiretroviral therapy in a longitudinal population cohort study.
来源期刊：Antiviral therapyDOI：10.3851/IMP3287
Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.
来源期刊：Antiviral therapyDOI：10.3851/IMP3294
Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.
来源期刊：Antiviral therapyDOI：10.3851/IMP3305
Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.
来源期刊：Antiviral therapyDOI：10.3851/IMP3327
Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
来源期刊：Antiviral therapyDOI：10.3851/IMP3304
Inhibitory effect of iota-carrageenan on porcine reproductive and respiratory syndrome virus in vitro.
来源期刊：Antiviral therapyDOI：10.3851/IMP3295
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
来源期刊：Antiviral therapyDOI：10.3851/IMP3301
Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales.
来源期刊：Antiviral therapyDOI：10.3851/IMP3317
No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration.
来源期刊：Antiviral therapyDOI：10.3851/IMP3324
Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
来源期刊：Antiviral therapyDOI：10.3851/IMP3341
MiRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis c associated lymphomas is restored by successful interferon-free antiviral therapy.
来源期刊：Antiviral therapyDOI：10.3851/IMP3322
Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.
来源期刊：Antiviral therapyDOI：10.3851/IMP3311
Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis.
来源期刊：Antiviral therapyDOI：10.3851/IMP3313
Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors.
来源期刊：Antiviral therapyDOI：10.3851/IMP3335
Vitamin D does not modulate immune-mediated bone loss during ART initiation.
来源期刊：Antiviral therapyDOI：10.3851/IMP3316
Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.
来源期刊：Antiviral therapyDOI：10.3851/IMP3291
Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
来源期刊：Antiviral therapyDOI：10.3851/IMP3297
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients.
来源期刊：Antiviral therapyDOI：10.3851/IMP3275
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.
来源期刊：Antiviral therapyDOI：10.3851/IMP3308
Tenofovir plus hepatitis B immunoglobulin treatment resulted in a rapid HBV DNA load decline in high-risk pregnant women who missed the optimal time window of antiviral prophylaxis.
来源期刊：Antiviral therapyDOI：10.3851/IMP3284
The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
来源期刊：Antiviral therapyDOI：10.3851/IMP3310
Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
来源期刊：Antiviral therapyDOI：10.3851/IMP3330
Adoptive T-cell therapy with CD45RA-deplected donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients.
来源期刊：Antiviral therapyDOI：10.3851/IMP3307
Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.
来源期刊：Antiviral therapyDOI：10.3851/IMP3302
Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
来源期刊：Antiviral therapyDOI：10.3851/IMP3303
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.
来源期刊：Antiviral therapyDOI：10.3851/IMP3296
HSV susceptibility to acyclovir - genotypic and phenotypic characterization.
来源期刊：Antiviral therapyDOI：10.3851/IMP3279
Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.
来源期刊：Antiviral therapyDOI：10.3851/imp3338
Low vitamin D is associated with coronary atherosclerosis in women with HIV.
来源期刊：Antiviral therapyDOI：10.3851/IMP3336
Association of serum total cholesterol with pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.
来源期刊：Antiviral therapyDOI：10.3851/IMP3282
Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia.
来源期刊：Antiviral therapyDOI：10.3851/IMP3299
Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.
来源期刊：Antiviral therapyDOI：10.3851/IMP3332
Antiviral activity of 4-oxoquinoline-3-carboxamide derivatives against bovine herpesvirus type 5.
来源期刊：Antiviral therapyDOI：10.3851/IMP3329
Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).
来源期刊：Antiviral therapyDOI：10.3851/IMP3298
Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors.
来源期刊：Antiviral therapyDOI：10.3851/IMP3339
Perillyl alcohol and perillic acid exert efficient action upon HSV-1 maturation and release of infective virus.
来源期刊：Antiviral therapyDOI：10.3851/IMP3315
Retraction: Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.
来源期刊：Antiviral therapyDOI：10.3851/IMP3325
HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.
来源期刊：Antiviral therapyDOI：10.3851/IMP3292

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学3区
INFECTIOUS DISEASES 传染病学
3区
PHARMACOLOGY & PHARMACY 药学
3区
VIROLOGY 病毒学
3区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
INFECTIOUS DISEASES 传染病学
4区
PHARMACOLOGY & PHARMACY 药学
4区
VIROLOGY 病毒学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
INFECTIOUS DISEASES 传染病学
4区
PHARMACOLOGY & PHARMACY 药学
4区
VIROLOGY 病毒学
4区
否
否